What is Kallyope?
Headquartered at the Alexandria Center for Life Science in New York City, Kallyope is a leading biotechnology enterprise dedicated to identifying and pursuing novel therapeutics involving the gut-brain axis. The company utilizes a cross-disciplinary methodology that integrates advanced sequencing, bioinformatics, neural imaging, and molecular biology. By decoding the intricate communication pathways within the gut-brain axis, Kallyope aims to develop transformational treatments that address significant unmet needs in human health, positioning itself at the forefront of precision medicine and therapeutic innovation.
How much funding has Kallyope raised?
Kallyope has raised a total of $486.1M across 5 funding rounds:
Private Equity
$28.1M
Series A
$44M
Series B
$66M
Series C
$112M
Series D
$236M
Private Equity (2015): $28.1M, investors not publicly disclosed
Series A (2015): $44M led by Lux Capital, The Column Group, Alexandria Venture, Illumina Inc, and Polaris Partners
Series B (2018): $66M supported by Lux Capital, Alexandria, EUCLIDEAN CAPITAL, The Column Group, Two Sigma Ventures, Illumina Ventures, and Polaris Partners
Series C (2020): $112M featuring Greenspring Associates Inc, The Column Group, Two Sigma Ventures, Illumina Ventures, Polaris Partners, Bill Gates, Casdin Capital , LLC, Lux Capital, Euclidean Capital, and Alexandria Venture Investments
Series D (2022): $236M backed by Mubadala and The Column Group
Key Investors in Kallyope
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model that nurtures platforms from inception to exit.
Lux Capital
Lux Capital is a New York-based venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, backing founders in frontier areas like biotechnology.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, providing coaching and resources to foster innovation.
What's next for Kallyope?
Following its latest major strategic investment, Kallyope is well-positioned to accelerate its clinical development pipeline and expand its technological infrastructure. The company's trajectory suggests a transition toward late-stage clinical trials and potential commercialization of its lead therapeutic candidates. By leveraging its deep expertise in genomics and neural biology, Kallyope is expected to continue attracting high-profile institutional support as it scales its operations to address systemic health challenges through its innovative, data-driven platform.
See full Kallyope company page
